Analysts Predict 15% Upside For The Holdings of IJR

The iShares Core S&P Small-Cap ETF (IJR) has an implied analyst 12-month target price of $129.77, suggesting a 14.93% upside from its recent trading price of $112.91 based on the weighted average of its underlying holdings. Specific constituents like Acadia Pharmaceuticals (ACAD), Carter's (CRI), and Alarm.com (ALRM) are highlighted for individual analyst-projected upsides ranging from 20% to 24%. The analysis prompts investors to evaluate the justification of these targets and conduct further research into their validity.

Analysis

Based on a weighted average of its underlying holdings' analyst price targets, the iShares Core S&P Small-Cap ETF (IJR) has an implied 12-month target of $129.77, representing a 14.93% potential upside from its recent price of $112.91. This aggregate forecast is supported by notable individual holdings with significant analyst-projected gains, including Acadia Pharmaceuticals (ACAD) with 24.50% upside, Carter's Inc. (CRI) with 21.67% upside, and Alarm.com Holdings (ALRM) with 20.91% upside. While these figures suggest a bullish consensus on select small-cap names, the analysis is accompanied by a cautionary tone, questioning whether these targets are genuinely forward-looking or merely outdated relics susceptible to future downgrades. The substantial gap between current trading prices and analyst targets introduces a key risk that these optimistic forecasts may not materialize if underlying company or industry fundamentals falter.

Key Decisions for Investors

• Investors could interpret the 14.93% implied upside in IJR as a constructive signal for the small-cap segment, but should verify this by examining the health of the ETF's broader holdings beyond the three examples provided.